Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
Date:2/17/2011

SEATTLE, Feb. 17, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the 2011 Genitourinary Cancers Symposium annual meeting in Orlando, Florida.

  • "Subsequent Treatment with APC8015F May Have Prolonged Survival of the Control Arm in Phase 3 Sipuleucel-T Studies," abstract #139.  Reception and General Poster Session B: Prostate Cancer (A33) from 4:50 to 6:20 p.m. ET on Thursday, February 17, 2011.
  • "Characterization of Antigen-Specific T cell Activation and Cytokine Expression Induced by Sipuleucel-T," abstract #155. Reception and General Poster Session B: Prostate Cancer (A49) from 4:50 to 6:20 p.m. ET on Thursday, February 17, 2011.

Abstract #139: Subsequent Treatment with APC8015F May Have Prolonged Survival of the Control Arm in Phase 3 Sipuleucel-T Studies

This exploratory analysis evaluated the survival of patients who were randomized to the control arm in the three metastatic castrate resistant prostate cancer PROVENGE® (sipuleucel-T) Phase 3 clinical trials (D9901, D9902A, D9902B).  Control used in the trial was non-activated autologous peripheral blood mononuclear cells.  Patients in these trials who were randomized to receive control had the opportunity to participate in an open label Phase 2 protocol that allowed them to receive APC8015F, an investigational autologous cellular immunotherapy made from cryopreserved cells at the time of control generation.

Results from the exploratory analysis show patients treated with APC8015F (n=155) after their disease progressed had improved survival relative to the patients not treated in the control arm (n=61).  Following disease progression, the median survival of patients treated with APC8015F was 20.0 months compared to 9.8 months for control patient
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Delaware , August 3, 2015 ... in the commercialization of its Bio-electrical Signal Therapy device ... noninvasive treatment of hard to heal chronic wounds, today ... agreement with Chemipal, an Israeli distributor specializing in medical ... device. Chemipal is a 70 years old, ...
(Date:7/31/2015)... VEGAS , July 31, 2015 ... seek resources that help them drive positive health ... a vital source of patient care in their ... annual tradeshow and conference, AmerisourceBergen announced a ... its Pharmacy Services Administration Organization and help independent ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary ... of its canine osteoarthritis stem cell product, currently under development for FDA approval. ... will be marketed in the US by Aratana. This product, termed AT-016, is ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... May 3, 2012 PDL BioPharma, Inc. (PDL) (NASDAQ: ... quarter ended March 31, 2012. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO ) ... 2012 increased five percent over the same period of 2011. ... million, compared to $83.3 million for the same period of ...
... Having headquarters in one of the  world,s largest democracies ... sought after exporters of Hospital Furniture and Orthopedic Implants. Product ... are some of the unique selling propositions of the organization. ... for quite a few years now. We are very happy ...
... 3, 2012  Discovery Laboratories, Inc. (Nasdaq: DSCO ... new standard in respiratory critical care, today reports financial ... The Company will host a conference call this morning ... Key financial information includes: , For ...
Cached Biology Technology:PDL BioPharma Announces First Quarter 2012 Financial Results 2PDL BioPharma Announces First Quarter 2012 Financial Results 3PDL BioPharma Announces First Quarter 2012 Financial Results 4PDL BioPharma Announces First Quarter 2012 Financial Results 5Customer Satisfaction, A key to Success: Narang Medical Limited 2Discovery Labs Reports First Quarter 2012 Financial Results 2Discovery Labs Reports First Quarter 2012 Financial Results 3Discovery Labs Reports First Quarter 2012 Financial Results 4Discovery Labs Reports First Quarter 2012 Financial Results 5Discovery Labs Reports First Quarter 2012 Financial Results 6Discovery Labs Reports First Quarter 2012 Financial Results 7Discovery Labs Reports First Quarter 2012 Financial Results 8Discovery Labs Reports First Quarter 2012 Financial Results 9Discovery Labs Reports First Quarter 2012 Financial Results 10Discovery Labs Reports First Quarter 2012 Financial Results 11
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik (ICG-10, ... vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ihr ... ICG weltweit zu einem der einflussreichsten jährlichen Treffen ... dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/31/2015)... SHENZHEN, China , July 31, 2015 The ... ) will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th ... become one of the world,s most influential annual meetings in ... enthusiastic, and enjoyable scientific gatherings. ICG-10 focuses ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... The University of Nottingham have taken some important first ... cell, a leading science journal reports. Dr Cameron ... School of Pharmacy have used polymers long-chain molecules ... the surfaces of a real cell. In work ...
... Des Moines, Iowa May 22, 2008 Dr. ... Trust of Iowa and a pioneer in the field ... eighth honorary doctor of science degree conferred in the ... at Springfield. Savage-Rumbaugh, an internationally known primatologist and ...
... unique ability to eat toxic mulberry leaves without feeling ... understanding why: silkworms contain a special digestive enzyme that ... leaves contain an extremely high amount of alkaloids that ... are potentially quite toxic. However, one type of sucrase ...
Cached Biology News:Life, but not as we know it? 2Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 2Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 3Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 4Ape language pioneer Savage-Rumbaugh receives honorary Ph.D. from alma mater 5
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
VAP-1 (S-13)...
... contains 4 deuterium atoms at the 3, ... intended for use as an internal standard ... by GC- or LC-mass spectrometry. PGE2 is ... arachidonic acid and one of the most ...
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Biology Products: